Wird geladen...
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
BACKGROUND: Second line of treatment of hepatocellular carcinoma (HCC) has notably changed in recent years as three novel drugs with a different mechanism of action have demonstrated to improve survival compared to placebo; thus, there is a need to better define the profile of optimal candidates to...
Gespeichert in:
| Veröffentlicht in: | J Oncol |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Hindawi
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7321521/ https://ncbi.nlm.nih.gov/pubmed/32655640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8024124 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|